The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) will be hold in Jinan, Shandong Province from September 10 to 14. Centered on the theme "Standardized Diagnosis and Treatment, Innovation-Driven", the conference showcases China's most cutting-edge and influential research achievements in clinical oncology, focusing on clinical needs and sharing practical experience. Multiple research findings from Scitech Pharma's ST-1898 and ST-1703 projects were selected for presentation in the Innovative Drug Clinical Research Data Session and the Malignant Melanoma Session, respectively.

On May 14, 2025, the clinical trial project “Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ST-1898 Tablets in Patients with Inoperable Resectable or Metastatic Melanoma” was successfully initiated at Beijing GoBroad Hospital.

On the afternoon of March 17, 2025, Nanjing Tianyinshan Hospital welcomed the launch of two clinical trial projects, bringing hope to thyroid cancer and melanoma patients. The meeting was co-chaired by Professor Qin Shukui, an internationally and domestically renowned oncology clinical research expert, and Director Chen Yingxia, Director of the Institutional Office.

On March 17, 2025, the kick-off meeting of two Phase II clinical trial projects of Scitech Pharma was held at Nanjing Tianyinshan Hospital affiliated with China Pharmaceutical University.

On December 10, 2024, the signing ceremony of the strategic cooperation agreement was held in Beijing between Beijing Scitech-MQ Pharmaceuticals Limited (Scitech Pharma) and Zhejiang Jiuzhou Pharmaceutical Limited (Jiuzhou Pharma).

Beijing Scitech-MQ Pharmaceuticals Limited (hereinafter referred to as "Scitech Pharma"), a leading Artificial Intelligence (AI)-driven drug discovery company, announced it has raised over RMB100 million in a Series A+ financing round.

On November 14, 2023, the registered clinical trial project “Multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial to evaluate the efficacy and safety of ST-1898 tablets for the treatment of locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer that has failed at least one line of TKI therapy” was successfully initiated at the Peking Union Medical College Hospital (PUMC).

On October 17, 2023, the clinical trial program of "Phase Ib/II Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ST-1898 Tablets in Patients with Non-surgically Resectable or Metastatic Melanoma" was successfully initiated at Beijing Cancer Hospital.